All Studies Meta Analysis

Real-World Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19

Webb et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab331

Jun 2021

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

Casirivimab/imdevimab

17th treatment shown to reduce risk in March 2021, now with p = 0.00036 from 31 studies, recognized in 45 countries. Efficacy is variant dependent.

Lower risk for hospitalization, progression, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,100+ studies for 112 treatments. c19early.org

Retrospective 115 patients treated with casirivimab/imdevimab showing lower mortality, hospital admission, and emergency department visits with treatment. Authors incorrectly state that "no other COVID-19 therapies for ambulatory patients have proven effective".

Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for many omicron variants1-7.

Important missing comments or errors? Let us know.

Study covers casirivimab/imdevimab and bamlanivimab/etesevimab.

risk of death, 98.3% lower, RR 0.02, p = 0.63, treatment 0 of 115 (0.0%), control 57 of 5,536 (1.0%), NNT 97, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).

risk of hospitalization, 91.1% lower, RR 0.09, p < 0.001, treatment 1 of 115 (0.9%), control 538 of 5,536 (9.7%), NNT 11.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. Liu et al., Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2, bioRxiv, doi:10.1101/2021.12.14.472719.biorxiv.org, doi.org.

2. Sheward et al., Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron), bioRxiv, doi:10.1101/2021.12.19.473354.biorxiv.org, doi.org.

3. VanBlargan et al., An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies, bioRxiv, doi:10.1101/2021.12.15.472828.biorxiv.org, doi.org.

4. Tatham et al., Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV 2 Omicron variant (B.1.1.529) in K18-hACE2 mice, bioRxiv, doi:10.1101/2022.01.23.477397.biorxiv.org, doi.org.

5. Pochtovyi et al., In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, Vaccines, doi:10.3390/vaccines11101533.mdpi.com, doi.org.

6. Haars et al., Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023, Microorganisms, doi:10.3390/microorganisms11102417.mdpi.com, doi.org.

7. Uraki et al., Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate, iScience, doi:10.1016/j.isci.2023.108147.sciencedirect.com, doi.org.

Webb et al., 23 Jun 2021, retrospective, USA, peer-reviewed, 14 authors.

This Paper Casirivimab/i..All

Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19

MD Brandon J Webb, Whitney Buckel, Todd Vento, Allison M Butler, Nancy Grisel, Samuel M Brown, Ithan D Peltan, Emily S Spivak, Mark Shah, Theadora Sakata, Anthony Wallin, Eddie Stenehjem, Greg Poulsen, Joseph Bledsoe

Open Forum Infectious Diseases, doi:10.1093/ofid/ofab331

Background. Neutralizing monoclonal antibodies (MAbs) are a promising therapy for early coronavirus disease 2019 , but their effectiveness has not been confirmed in a real-world setting. Methods. In this quasi-experimental pre-/postimplementation study, we estimated the effectiveness of MAb treatment within 7 days of symptom onset in high-risk ambulatory adults with COVID-19. The primary outcome was a composite of emergency department visits or hospitalizations within 14 days of positive test. Secondary outcomes included adverse events and 14-day mortality. The average treatment effect in the treated for MAb therapy was estimated using inverse probability of treatment weighting and the impact of MAb implementation using propensity-weighted interrupted time series analysis. Results. Pre-implementation (July-November 2020), 7404 qualifying patients were identified. Postimplementation (December 2020-January 2021), 594 patients received MAb treatment and 5536 did not. The primary outcome occurred in 75 (12.6%) MAb recipients, 1018 (18.4%) contemporaneous controls, and 1525 (20.6%) historical controls. MAb treatment was associated with decreased likelihood of emergency care or hospitalization (odds ratio, 0.69; 95% CI, 0.60-0.79). After implementation, the weighted probability that a given patient would require an emergency department visit or hospitalization decreased significantly (0.7% per day; 95% CI, 0.03%-0.10%). Mortality was 0.2% (n = 1) in the MAb group compared with 1.0% (n = 71) and 1.0% (n = 57) in pre-and postimplementation controls, respectively. Adverse events occurred in 7 (1.2%); 2 (0.3%) were considered serious. Conclusions. MAb treatment of high-risk ambulatory patients with early COVID-19 was well tolerated and likely effective at preventing the need for subsequent emergency department or hospital care.

Supplementary Data Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

References

Austin, Stuart, Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies, Stat Med

Cevik, Tate, Lloyd, SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis, Lancet Microbe

Charlson, Pompei, Ales, Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis

Chatellier, Zapletal, Lemaitre, The number needed to treat: a clinically useful nomogram in its proper context, BMJ

Chen, Nirula, Heller, BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med

Elixhauser, Steiner, Harris, Coffey, Comorbidity measures for use with administrative data, Med Care

Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA

Libster, Marc, Wappner, Fundación INFANT-COVID-19 Group. Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N Engl J Med

Rubin, Estimating causal effects from large data sets using propensity scores, Ann Intern Med

Wagner, Soumerai, Zhang, Ross-Degnan, Segmented regression analysis of interrupted time series studies in medication use research, J Clin Pharm Ther

Webb, Levin, Grisel, Simple scoring tool to estimate risk of hospitalization and mortality in ambulatory and emergency department patients with COVID-19, MedRxiv, doi:10.1101/2021.02.22.21252171

Weinreich, Sivapalasingam, Norton, Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med

{ 'indexed': {'date-parts': [[2024, 3, 11]], 'date-time': '2024-03-11T21:07:10Z', 'timestamp': 1710191230929}, 'reference-count': 15, 'publisher': 'Oxford University Press (OUP)', 'issue': '7', 'license': [ { 'start': { 'date-parts': [[2021, 6, 23]], 'date-time': '2021-06-23T00:00:00Z', 'timestamp': 1624406400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 7, 1]]}, 'abstract': 'Abstract\n' ' \n' ' Background\n' ' Neutralizing monoclonal antibodies (MAbs) are a promising therapy ' 'for early coronavirus disease 2019 (COVID-19), but their effectiveness has not been confirmed ' 'in a real-world setting.\n' ' \n' ' \n' ' Methods\n' ' In this quasi-experimental pre-/postimplementation study, we ' 'estimated the effectiveness of MAb treatment within 7 days of symptom onset in high-risk ' 'ambulatory adults with COVID-19. The primary outcome was a composite of emergency department ' 'visits or hospitalizations within 14 days of positive test. Secondary outcomes included ' 'adverse events and 14-day mortality. The average treatment effect in the treated for MAb ' 'therapy was estimated using inverse probability of treatment weighting and the impact of MAb ' 'implementation using propensity-weighted interrupted time series analysis.\n' ' \n' ' \n' ' Results\n' ' Pre-implementation (July–November 2020), 7404 qualifying patients ' 'were identified. Postimplementation (December 2020–January 2021), 594 patients received MAb ' 'treatment and 5536 did not. The primary outcome occurred in 75 (12.6%) MAb recipients, 1018 ' '(18.4%) contemporaneous controls, and 1525 (20.6%) historical controls. MAb treatment was ' 'associated with decreased likelihood of emergency care or hospitalization (odds ratio, 0.69; ' '95% CI, 0.60–0.79). After implementation, the weighted probability that a given patient would ' 'require an emergency department visit or hospitalization decreased significantly (0.7% per ' 'day; 95% CI, 0.03%–0.10%). Mortality was 0.2% (n\u2005=\u20051) in the MAb group compared ' 'with 1.0% (n\u2005=\u200571) and 1.0% (n\u2005=\u200557) in pre- and postimplementation ' 'controls, respectively. Adverse events occurred in 7 (1.2%); 2 (0.3%) were considered ' 'serious.\n' ' \n' ' \n' ' Conclusions\n' ' MAb treatment of high-risk ambulatory patients with early COVID-19 ' 'was well tolerated and likely effective at preventing the need for subsequent emergency ' 'department or hospital care.\n' ' ', 'DOI': '10.1093/ofid/ofab331', 'type': 'journal-article', 'created': {'date-parts': [[2021, 6, 23]], 'date-time': '2021-06-23T01:00:39Z', 'timestamp': 1624410039000}, 'source': 'Crossref', 'is-referenced-by-count': 42, 'title': 'Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients ' 'With Early COVID-19', 'prefix': '10.1093', 'volume': '8', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-1799-3315', 'authenticated-orcid': False, 'given': 'Brandon J', 'family': 'Webb', 'sequence': 'first', 'affiliation': [ { 'name': 'Division of Infectious Diseases and Clinical Epidemiology, ' 'Intermountain Healthcare, Salt Lake City, Utah, USA'}, { 'name': 'Division of Infectious Diseases and Geographic Medicine, ' 'Stanford Medicine, Palo Alto, California, USA'}]}, { 'given': 'Whitney', 'family': 'Buckel', 'sequence': 'additional', 'affiliation': [ { 'name': 'Pharmacy Services, Intermountain Healthcare, Salt Lake City, ' 'Utah, USA'}]}, { 'given': 'Todd', 'family': 'Vento', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Infectious Diseases and Clinical Epidemiology, ' 'Intermountain Healthcare, Salt Lake City, Utah, USA'}]}, { 'given': 'Allison M', 'family': 'Butler', 'sequence': 'additional', 'affiliation': [ { 'name': 'Enterprise Analytics, Intermountain Healthcare, Salt Lake City, ' 'Utah, USA'}]}, { 'given': 'Nancy', 'family': 'Grisel', 'sequence': 'additional', 'affiliation': [ { 'name': 'Enterprise Analytics, Intermountain Healthcare, Salt Lake City, ' 'Utah, USA'}]}, { 'given': 'Samuel M', 'family': 'Brown', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Pulmonary and Critical Care Medicine, Intermountain ' 'Medical Center and University of Utah, Salt Lake City, Utah, ' 'USA'}]}, { 'given': 'Ithan D', 'family': 'Peltan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Pulmonary and Critical Care Medicine, Intermountain ' 'Medical Center and University of Utah, Salt Lake City, Utah, ' 'USA'}]}, { 'given': 'Emily S', 'family': 'Spivak', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Infectious Diseases, University of Utah School of ' 'Medicine, Salt Lake City, Utah, USA'}]}, { 'given': 'Mark', 'family': 'Shah', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Emergency Medicine, Intermountain Healthcare, Salt ' 'Lake City, Utah, USA'}]}, { 'given': 'Theadora', 'family': 'Sakata', 'sequence': 'additional', 'affiliation': [ { 'name': 'Urgent Care Service Line, Intermountain Healthcare, Salt Lake ' 'City, Utah, USA'}]}, { 'given': 'Anthony', 'family': 'Wallin', 'sequence': 'additional', 'affiliation': [ { 'name': 'Urgent Care Service Line, Intermountain Healthcare, Salt Lake ' 'City, Utah, USA'}]}, { 'given': 'Eddie', 'family': 'Stenehjem', 'sequence': 'additional', 'affiliation': [ { 'name': 'Division of Infectious Diseases and Clinical Epidemiology, ' 'Intermountain Healthcare, Salt Lake City, Utah, USA'}, { 'name': 'Division of Infectious Diseases and Geographic Medicine, ' 'Stanford Medicine, Palo Alto, California, USA'}, { 'name': 'Office of Patient Experience, Intermountain Healthcare, Salt ' 'Lake City, Utah, USA'}]}, { 'given': 'Greg', 'family': 'Poulsen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Executive Leadership Team, Intermountain Healthcare, Salt Lake ' 'City, Utah, USA'}]}, { 'given': 'Joseph', 'family': 'Bledsoe', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Emergency Medicine, Intermountain Healthcare, Salt ' 'Lake City, Utah, USA'}, { 'name': 'Department of Emergency Medicine, Stanford Medicine, Palo Alto, ' 'California, USA'}]}], 'member': '286', 'published-online': {'date-parts': [[2021, 6, 23]]}, 'reference': [ { 'key': '2021072712513475600_CIT0001', 'doi-asserted-by': 'crossref', 'first-page': '880', 'DOI': '10.1001/jama.2020.24415', 'article-title': 'An EUA for bamlanivimab—a monoclonal', 'volume': '325', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': '2021072712513475600_CIT0002', 'first-page': '201', 'article-title': 'An EUA for casirivimab and imdevimab for COVID-19', 'volume': '62', 'year': '2020', 'journal-title': 'Med Lett Drugs Ther'}, { 'key': '2021072712513475600_CIT0003', 'doi-asserted-by': 'crossref', 'first-page': '229', 'DOI': '10.1056/NEJMoa2029849', 'article-title': 'SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19', 'volume': '384', 'author': 'Chen', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '2021072712513475600_CIT0004', 'doi-asserted-by': 'crossref', 'first-page': '632', 'DOI': '10.1001/jama.2021.0202', 'article-title': 'Effect of bamlanivimab as monotherapy or in combination with etesevimab ' 'on viral load in patients with mild to moderate COVID-19: a randomized ' 'clinical trial', 'volume': '325', 'author': 'Gottlieb', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': '2021072712513475600_CIT0005', 'doi-asserted-by': 'crossref', 'first-page': '238', 'DOI': '10.1056/NEJMoa2035002', 'article-title': 'REGN-COV2, a neutralizing antibody cocktail, in outpatients with ' 'Covid-19', 'volume': '384', 'author': 'Weinreich', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '2021072712513475600_CIT0006', 'doi-asserted-by': 'crossref', 'first-page': '373', 'DOI': '10.1016/0021-9681(87)90171-8', 'article-title': 'A new method of classifying prognostic comorbidity in longitudinal ' 'studies: development and validation', 'volume': '40', 'author': 'Charlson', 'year': '1987', 'journal-title': 'J Chronic Dis'}, { 'key': '2021072712513475600_CIT0007', 'doi-asserted-by': 'crossref', 'first-page': '8', 'DOI': '10.1097/00005650-199801000-00004', 'article-title': 'Comorbidity measures for use with administrative data', 'volume': '36', 'author': 'Elixhauser', 'year': '1998', 'journal-title': 'Med Care'}, { 'key': '2021072712513475600_CIT0008', 'volume-title': 'Utah Department of Health and Utah Hospital Association'}, { 'key': '2021072712513475600_CIT0009', 'article-title': 'Simple scoring tool to estimate risk of hospitalization and mortality ' 'in ambulatory and emergency department patients with COVID-19', 'author': 'Webb', 'year': '2021', 'journal-title': 'MedRxiv'}, { 'key': '2021072712513475600_CIT0010', 'doi-asserted-by': 'crossref', 'first-page': '757', 'DOI': '10.7326/0003-4819-127-8_Part_2-199710151-00064', 'article-title': 'Estimating causal effects from large data sets using propensity scores', 'volume': '127', 'author': 'Rubin', 'year': '1997', 'journal-title': 'Ann Intern Med'}, { 'key': '2021072712513475600_CIT0011', 'doi-asserted-by': 'crossref', 'first-page': '3661', 'DOI': '10.1002/sim.6607', 'article-title': 'Moving towards best practice when using inverse probability of ' 'treatment weighting (IPTW) using the propensity score to estimate ' 'causal treatment effects in observational studies', 'volume': '34', 'author': 'Austin', 'year': '2015', 'journal-title': 'Stat Med'}, { 'key': '2021072712513475600_CIT0012', 'doi-asserted-by': 'crossref', 'first-page': '426', 'DOI': '10.1136/bmj.312.7028.426', 'article-title': 'The number needed to treat: a clinically useful nomogram in its proper ' 'context', 'volume': '312', 'author': 'Chatellier', 'year': '1996', 'journal-title': 'BMJ'}, { 'key': '2021072712513475600_CIT0013', 'doi-asserted-by': 'crossref', 'first-page': '299', 'DOI': '10.1046/j.1365-2710.2002.00430.x', 'article-title': 'Segmented regression analysis of interrupted time series studies in ' 'medication use research', 'volume': '27', 'author': 'Wagner', 'year': '2002', 'journal-title': 'J Clin Pharm Ther'}, { 'key': '2021072712513475600_CIT0014', 'doi-asserted-by': 'crossref', 'first-page': '610', 'DOI': '10.1056/NEJMoa2033700', 'article-title': 'Early high-titer plasma therapy to prevent severe Covid-19 in older ' 'adults', 'volume': '384', 'author': 'Libster', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '2021072712513475600_CIT0015', 'doi-asserted-by': 'crossref', 'first-page': 'e13', 'DOI': '10.1016/S2666-5247(20)30172-5', 'article-title': 'SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of ' 'viral shedding, and infectiousness: a systematic review and ' 'meta-analysis', 'volume': '2', 'author': 'Cevik', 'year': '2021', 'journal-title': 'Lancet Microbe'}], 'container-title': 'Open Forum Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab331/38814041/ofab331.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/ofid/article-pdf/8/7/ofab331/39337375/ofab331.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/ofid/article-pdf/8/7/ofab331/39337375/ofab331.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 7, 27]], 'date-time': '2021-07-27T12:52:09Z', 'timestamp': 1627390329000}, 'score': 1, 'resource': {'primary': {'URL': 'https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofab331/6308074'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 6, 23]]}, 'references-count': 15, 'journal-issue': {'issue': '7', 'published-print': {'date-parts': [[2021, 7, 1]]}}, 'URL': 'http://dx.doi.org/10.1093/ofid/ofab331', 'relation': { 'has-preprint': [ { 'id-type': 'doi', 'id': '10.1101/2021.03.15.21253646', 'asserted-by': 'object'}]}, 'ISSN': ['2328-8957'], 'subject': ['Infectious Diseases', 'Oncology'], 'published-other': {'date-parts': [[2021, 7, 1]]}, 'published': {'date-parts': [[2021, 6, 23]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0